KRT14 and Hyperkeratosis: Interestingly, we found that after treatment with QBX258, these pathological changes improved in the lymphedematous limb, and, for the most part, returned to normal levels noted in the unaffected limb (hyperkeratosis, p < 0.01; Ki67+ cells, p < 0.05; KRT14 p < 0.001).